Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
Scholar Rock (NASDAQ: SRRK) provided updates on its clinical programs, indicating pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023. The DRAGON trial of SRK-181 is also advancing, showing early efficacy signals. The company anticipates sufficient cash runway into 2025, supported by a $205 million equity raise completed in June 2022, with current cash reserves around $315 million. Upcoming milestones include 36-month data from the Phase 2 TOPAZ trial and progress on preclinical assets targeting fibrosis and iron-restricted anemia.
- Pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023.
- Early signs of efficacy reported in Phase 1 DRAGON trial of SRK-181.
- Anticipated cash runway into 2025, supported by previous $205 million equity raise.
- None.
- Pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023
- Phase 1 DRAGON trial of SRK-181 continues to advance with presented data that showed early indications of efficacy; ongoing clinical data updates planned in 2023
- Anticipated cash runway into 2025
“In 2022,
2023 Priorities:
Apitegromab is a selective inhibitor of myostatin activation being developed as the potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA).
- Complete enrollment of Phase 3 SAPPHIRE clinical trial in 2023. SAPPHIRE is a randomized, double-blind, placebo-controlled clinical trial evaluating apitegromab for patients with nonambulatory Types 2 and 3 SMA on either nusinersen or risdiplam. The last patient is expected to be enrolled in SAPPHIRE in 2023, with the top-line data readout expected in 2024. If successful, the company expects to initiate a commercial product launch in 2025.
-
Progress TOPAZ long-term extension to 36-month data readout. The company expects to report 36-month extension data in the first half of 2023. As of
December 31, 2022 , approximately 90 percent of patients (51/57) remained enrolled in the trial’s long-term extension period.
SRK-181 is an investigational selective inhibitor of latent TGFβ-1 activation and is being developed with the aim of overcoming resistance to checkpoint therapy in patients with advanced cancer.
-
Advance Progress in DRAGON Phase 1 trial.
Scholar Rock is expecting to provide biomarker and clinical updates from the DRAGON Phase 1 trial in 2023.
Preclinical fibrosis and iron-restricted anemia assets
-
Advance the fibrosis program towards IND-enabling studies.
Scholar Rock plans to advance a highly potent, anti-latent TGFβ-1 antibody that selectively inhibits TGFβ1 activation within the extracellular matrix by targeting latent TGFβ-1 associated with latent TGFβ-binding proteins (LTBPs), thus enabling specific inhibition of TGFβ-1 in fibrotic tissue.
-
Advance the iron-restricted anemia program towards IND-enabling studies.
Scholar Rock plans to advance a highly selective, RGMc/HJV antibody that targets the signaling of BMP6, a key regulator of iron availability in the body. Utilizing Scholar Rock’s unique structural biology insights into BMP6 and its co-receptors and leveraging its novel antibody discovery and optimization platform, the company generated an anti-RGMc antibody that can modulate iron release and has the potential to address anemia.
2022 Highlights:
- TOPAZ 24-month extension trial data showed sizeable and sustained gains in Hammersmith Functional Motor Scale Expanded (HFMSE), increased Revised Upper Limb Module (RULM), and positive trends in quality-of-life data for nonambulatory patients with Types 2 and 3 SMA receiving an SMN-targeted therapy.
-
Completed equity financing of
in June. As of$205 million December 31, 2022 ,Scholar Rock had cash, cash equivalents, and marketable securities of approximately , which is expected to fund the company’s operations into 2025.$315 million -
Phase 1 DRAGON trial data presented at the
Society for Immunotherapy of Cancer's Annual Meeting in November showed that SRK-181 continued to be generally well tolerated with early indications of efficacy (as of the data cut-off date ofAugust 29, 2022 ). -
Presented new data on LTBP showing reduction of TGFβ-1 signaling and fibrosis in relevant in vivo preclinical models. The findings were presented at the 2022
FASEB Science Research Conference in July and theAmerican College of Toxicology Annual Meeting in November. -
Announced
Jay Backstrom , M.D., M.P.H. was appointed President & CEO in October, bringing an exceptional range of research and development, regulatory, and leadership experience spanning several decades in the biopharmaceutical industry. -
Announced
Jing L. Marantz , M.D., Ph.D., M.B.A., was appointed Chief Medical Officer in November.Dr. Marantz is an accomplished biopharmaceutical executive with over 20 years of industry experience spanning multiple specialties, including neurology, hematology/oncology, and rare diseases.
“With our strong balance sheet and two well established clinical programs, both of which we expect to generate data in 2023,
About
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs,
Scholar Rock® is a registered trademark of
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial of apitegromab, or Part A of the Phase 1 clinical trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA or Part B of the Phase 1 clinical trial of SRK-181, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of current macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, hostilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005206/en/
Investors
Rushmie Nofsinger
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
ariane.lovell@finnpartners.com
media@scholarrock.com
917-565-2204
Source:
FAQ
What is the expected timeline for the SAPPHIRE trial completion for Scholar Rock (SRRK)?
What are the latest updates on the SRK-181 trial by Scholar Rock (SRRK)?